Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript

SA Transcripts 162.06K Followers Follow Protagonist Therapeutics, Inc. ( PTGX ) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera August 31, 2026 8:30 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Arturo Molina - Chief Medical Officer Asif Ali - Executive VP & CFO Ashok Bhandari - EVP & Chief Discovery Officer Conference Call Participants Corey Davis - Lifesci Advisors, LLC Alexandria Hammond - Wolfe Research, LLC Tara Bancroft - TD Cowen, Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Jiale Song - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Alexander Xenakis - Truist Securities, Inc., Research Division Nathanael Charoensook - Leerink Partners LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Yun Zhong - Wedbush Securities Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Welcome to the Protagonist Therapeutics conference call. [Operator Instructions] As a reminder, this call is being recorded today, Monday, August 31, 2026. I'll now turn the call over to Dr. Corey Davis of LifeSci Advisors. Please go ahead. Corey Davis Lifesci Advisors, LLC Thank you, Rob. Hello, everyone, and thanks for joining us on our call today. Joining me from Protagonist are Dr. Dinesh Patel, President and CEO; Asif Ali, CFO; Dr. Arturo Molina, CMO; Dr. Ashok Bhandari, Chief Discovery Officer; and Dr. Samuel Saks, Clinical Development Adviser. On Friday, Protagonist issued a press release announcing the FDA approval of rusfertide, now known as MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera or PV. A copy of the release and the slides being used for this call are available on the company's website. As can be seen on this slide, we will be making forward-looking statements on this call. These may include statements relating to the safety and efficacy and the therapeutic